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1 
A B S T R A C T 
An overview of the varied clinico-neurological features of dyskinesias in 
general is presented, and literature an the epidemiology af tardive 
dyskinesia since the introduction of antipsychotic drugs in 1950, 
reviewed. Furthermore reasons for the wide variations in previously 
published prevalence figures have been critically highlighted, and 
suggestions based upon the current state of clinical and experimental 
knowledge put forward concerning the pathogenesis of drug induced 
movement disorders. 
The type and prevalence of abnormal or purposeless involuntary movements 
has been surveyed among a large sample of long term White patients 
resident in Town Hill Hospital for a period of not less than 4 years, 
mast af whom were either currently receiving or had received neuroleptic 
medication. This sample comprised 190 men and 98 women whose ages ranged 
from the third to the ninth decade. Patients manifesting abnormal 
movements were grouped into 5 general diagnostic categories for analysis 
viz. schisophrenic disorders, affective disorders, organic brain 
disorders and syndromes, defective mental development and discrete 
neurological disorder. The movements were clinically classified in terms 
cf the areas of the body involved and semi quantitatively measured 
according to a standardised duration rating scale procedure. 
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Involuntary movements were noted to be present in a total o-f 83 patients 
examined, most o-f which were adjudged to correspond to the syndrome 
currently termed 'tardive dyskinesia'. Subtype analysis o-f movement 
distribution indicated that 277. of cases manifested classical oro-facial 
dyskinesia while 527. showed body dyskinesia o-f the type designated 
' pseudaakathisia'; the balance o-f the patients presented combinations o-f 
the two types. 
Schizophrenic disorders constituted the commonest diagnostic category in 
the dyskinesia group up to the fifth decade. Functionally obtrusive 
involuntary movements were observed in only some 77. of the patients with 
dyskinesia. Prevalence overall was equal between the sexes, and no 
correlations were discerned between age, sex, diagnosis or dyskinesia 
subtype of cases and the rating scores obtained. 
Prevalence rates obtained by this survey are favourably low by comparison 
with many results of overseas investigators, and are similar in this 
respect to figures reported in the very few prevalence studies carried 
out to date in South African institutions. 
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1.1 NATURE OF THE PROBLEM 
During the 19th century the study of abnormal involuntary body movements 
engaged the attention o-f physicians and neurologists who described a 
variety o-f symptom clusters emanating -from organic brain pathology. 
Following delineation of mental disorders as discrete clinical entities 
by Kraepelin and Bleuler in the early years of this century, psychiatric 
interest focussed on abnormal movements, presumably of functional origin, 
associated principally with psychotic mental states. Some fifty years 
later the advent of antipsychotic drugs introduced a neuropharmacological 
dimension to the problem of abnormal body movements. At present 
neuroleptics represent the most valuable single therapeutic tool 
available for treatment of major mental illness but they have been 
associated with the development of a range of unpleasant clinical 
sequelae including a potentially irreversible movement disorder. 
The clinical value of neuroleptic drugs lies in their ability to induce a 
state of tranquility without concomitant clouding of consciousness, a 
quality which has established these compounds as the mainstay of 
management of acute toxic ccnfusional and psychotic mental states. The 
longer term use of neuroleptics has been advocated for the control of 
chronic schizophrenic thought disorder and the prevention of acute 
relapses in schizophrenic outpatients (Hogarty and Ulrich,1977). Their 
widespread therapeutic application was closely associated with 
neurological side effects which appear to be intimately bound with and 
indeed may even parallel antipsychotic potency. Within the first few 
years of clinical usage there were a variety of reports indicating 
dystonic attacks and parkinsonism as complications presenting in the 
early phases of treatment, while an involuntary hyperkinesia was 
recognised as a later phenomenon (Berqer and Rexroth,1980). This delayed 
hyperkinetic syndrome was termed 'tardive dyskinesia' (Faurbye et 
al,1964) to signify a movement disorder that could manifest itself and 
persist for years, even after the discontinuation of treatment with the 
precipitating agent. The name 'tardive dyskinesia' (TD) has became 
generally accepted and recognised, although other designations have been 
used in the past to describe this condition including 'terminal 
extrapyramidal insufficiency syndrome', 'persistent extrapyramidal 
hyperkinesia' and 'complex dyskinesia' (Gerlach,1979). 
As will become evident later, TD thus represents a rather loosely defined 
clinical entity which is empirically related to usage of drugs which 
block dopamine receptors in the central nervous system. Some of the 
abnormal involuntary movements of TD are very like those encountered in 
other forms of dyskinesia produced by specific disease processes 
involving the basal ganglia. It is probably for this reason, at least in 
part, that studies attempting to define predisposing, precipitating and 
perpetuating factors in relation to TD have yielded inconclusive, varied 
and often conflicting findings. Currently doubt has been voiced 
concerning the use o-f the term TD to describe involuntary movements of 
di-f-ferent patterns and unpredictable response to medication (Kidger et 
al,1980), and there is a body of opinion favouring the view that TD 
represents a heterogenous group of disorders with a variety of 
anatomical, neuropathological and pathophysiological bases (Baldessarini 
et al,l?80>. 
1.2 RATIONALE FOR THE PROJECT 
Numerous surveys and studies have been conducted both on hospital 
residents and outpatient populations to establish the frequency of TD, 
and to establish parameters such as sen, age and type of underlying 
psychiatric disease that would have bearing on its appearance in patients 
exposed to neuroleptics. The results of the work to date are 
characterised by diversity rather than consensus and frequently the 
findings of one group of researchers have either not been confirmed, or 
even contradicted, by the observations of another group. 
Over the past four years no research data on the topic of TD have 
appeared that could be considered as contributing fundamentally new 
information, or that permit clarification of the many problems relating 
to its aetiology and epidemiology (Kane et al,l?85). Local South African 
prevalence surveys are sparse, and therefore of particular interest are 
the findings of 2 studies employing patient samples selected from chronic 
patients at the V'al ksnberg psychiatric hospital in Cape Town. 
In the first of these, a group of 196 institutionalised patients with 
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chronic mental illness was studied to determine the prevalence of 
unrecognised physical disease (Morris et al,1983); the cases examined 
were all White patients from three randomly selected 'chronic' wards. The 
authors noted that some 22 (ll'/J of these individuals manifested 
dyskinetic movements, some of which 'may have been due to tardive 
dyskinesia' (sic). The anatomical character, age distribution and 
severity of the dyskinesias was not defined, and neither the means of 
clinical assessment nor the clinical diagnoses of the patients 
manifesting abnormal movements were specified. Noteworthy within the 
context of the latter point is that 'organic psychosis' comprised some 35 
of the total sample, together with a few cases of epilepsy and 
Huntington's chorea; all but 2 of the 22 dyskinetic patients were 
females. 
More recently published was a survey designed specifically to determine 
the prevalence and subtype distribution of TD at the same hospital 
(Holden et al,l?84). This later study involved systematic examination of 
a larger sampling - 278 individuals - of White inpatients drawn also from 
long term stay wards, and which presumably represents a population 
overlapping, though not entirely identical with, that reported on 
previously by Morris. Neurological screening was employed and cases 
manifesting discrete neurological disorder were excluded; abnormal 
movements observed were rated on, a 4 point severity scale. Prevalence of 
TD in these patients was estimated to be 177. (25 males and 24 females), a 
figure which included 7 cases whose dyskinesia might have resulted from 
spontaneous oral dyskinesia, dental problems and organic brain syndrome -
omission of the latter cases lowered the prevalence to some 14"'.. The mean 
age of the 49 afflicted patients was 62 years, and 7 were over 80 years. 
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Classic orolingual symptoms were observed in only 307. (15 cases) o-f the 
TD group, the balance being variations o-f 'peripheral TD' (an arolingual 
component with permutations and combinations of abnormal movement in 
1imbs and body). 
Because a-f di-f-f erences in sampling and methodological approach it would 
be unwarranted to compare the results of these Valkenberg studies too 
closely, however the -findings overall suggest that TD prevalence inclines 
to be lower than that observed in psychiatric hospitals abroad. 
Furthermore it would appear that a simple global clinical assessment o-f 
TD (as likely employed in the earlier study, which was not instigated 
with the investigation of abnormal movements as a primary objective) can 
provide survey results that coincide passably well with those derived 
•from rating assessment. 
Computation based on a random sample of 100 Black psychiatric cases drawn 
from long term inpatients at Ekuhlengeni Sanatorium, Natal, indicates 
that overall TD prevalence in this racial group approaches 407. 
(Halden,1985). Although this prevalence was 'corrected' by the author to 
about 31% after exclusion of patients with no record of antipsychotic 
drug exposure, the role of race as a possible TD risk factor might be 
conjectured. 
1.3 AIM AND SCOPE OF THE PROJECT 
The objective of this survey was to determine the cross sectional 
prevalence of abnormal involuntary or purposeless movements in chronic 
institutionalised White patients of both sexes, at the Town Hill hospital 
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section of the Midlands Hospital Complex in Pietermaritzburg, Natal. This 
hospital is the only hospital in the province that provides long term 
residential care for this group of the mentally ill, and as such receives 
all patients from the entire province, although a few individuals from 
other parts of the Republic are also accomodated. The geographical 
drainage of Town Hill therefore cavers an area of some 86,967 square 
kilometres, serving a White population of 560,000 persons (Department of 
Statistics,Durban:1983). 
Such clearcut categorisation in terms of climatic and socio-cultural 
mileau proffers an excellent potential to expose possible covertly 
operative environmental risk factors. Furthermore local surveys of this 
nature published to date are few in number, being restricted to the 
couple of studies recently conducted at Cape Town's Valkenberg hospital 
to which reference has already been made. It seemed of no little 
importance therefore to carry out a demographic study at a second major 
psychiatric institution in the Republic, especially in view of the widely 
varying prevalence rates of TD reported in medical publications based on 
case surveys from other parts of the world over the past 25 years. 
The precise relationship of antipsychotic drugs to the phenomenon of 
movement disorders remains a topic of contentious debate and some 
investigators have presented evi-dence suggesting that abnormal movements 
primarily reflect organic degenerative pathogy in the central nervous 
system. This study was therefore designed with a view to delineating 
dyskinesia in terms of the diagnostic categories of patients involved, 
which hopefully might provide clues as to the pathogenesis of movement 
disorders in psychiatric patients as well as guidelines for possible 
future research. 
7 
1.4 HYPOTHETICAL BASE OF THE STUDY 
The hypothesis adopted at the outset of this investigation was 
that TD is a nonspecific clinical entity and represents simply a final 
common pathway of somatic expression for deteriorated functional 
integrity of the basal ganglia. It was further suggested that since 
abnormal involuntary body movements occur spontaneously as part of a 
natural aging brain process (the neurochemical components of which have 
not yet been unambiguously defined), neuroleptics might induce an 
iatrogenic equivalent by disturbing neurotransmitter equilibrium in the 
central nervous system. The fact that only certain persons develop 
dyskinesias indicates that degrees of individual neuroplasticity exist 
permitting buffering of the aforesaid dysequi1ibrium process, a quality 
which itself tends to lose flexibilty with age. Further elaboration of 
these paints appears in subsequent chapters of this dissertation, 




REVIEW OF LITERATURE 
2.1 DYSKINESIA - NEUROCLINICAL PERSPECTIVE 
2.1.1 Disorders of movement: dyskinesias 
Clinically the term 'dyskinesia' is applied to abnormal involuntary 
reasonably coordinated motor activity manifested in groups of skeletal 
muscles. Movements of this type should be contrasted with fibrillation, 
fasciculation and myokymia which represent activity in single muscle 
fibres or groups of fibres in an individual muscle. The dyskinesias 
therefore represent pathologically excessive movement (hyperkinesia) 
arising from functional disturbance of the extrapyramidal nervous system, 
especially the basal ganglia, by a mechanism known as 'release 
phenomenon' whereby the spontanepus rhythmic movements initiated by the 
motor carte:;, normally inhibited by the extrapyramidal system, are no 
longer suppressed. The movements thus 'released' may involve muscles of 
the head, limbs or trunk and range in amplitude from mild tremors to 
extremely gross violent jerks. 
o 
While the mechanisms, in anatomical and neurophysiological terms, 
underlying the production of such movement disorders are not always 
precisely understood, several well described clinical forms have been 
documented as follows: 
I - TREMORS (the main forms include familial or essential, 
senile, Parkinsonian, cerebellar, Wilson's disease, 
hepatic disease and toxins). 
II - CHOREIFORM MOVEMENTS (coarse, quick, jerky and 
quasi-purposeful). 
III - ATHETOID MOVEMENTS (arrhythmic, slow and sinuous). 
IV - MYOCLONUS (abrupt, irregular and spasmodic). 
V - BALLISM (sudden, coordinated limb flailing). 
VI - TICS or HABIT SPASMS (frequently of psychogenic origin but 
in some cases an organic component may be present). 
2.1.2 Disorders of tone: dystonias 
Dysfunction of the extrapyramidal nervous system produces, concomitant 
with the abnormal movements described above, associated disturbance of 
muscle tone the commonest being hypertonia. Dystonia usually refers to 
mobile spasms of the axial and proximal muscles of the extremities, and 
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dystonic movements tend to involve large portions of the body and have an 
undulant, sinuous character which may produce grotesque posturing and 
bizarre writhing movements - the familial disorder of dystonia musculorum 
deformans (or torsion spasm) represents a particularly disabling example 
of truncal dystonia. From a functional viewpoint chorea, athetosis and 
dystonia may be regarded as a series of disturbances which merge into one 
another. More localised dystonic states not infrequently encountered by 
psychiatrists include torticollis, retrocollis, oculogyric crisis, 
blepharospasm and writer's cramp (these latter two entities in particular 
have been commonly regarded as purely hysterical motor abnormalities, 
however there is evidence to suggest that psychogenic factors are not 
solely responsible, and covert brain pathology may in fact be operative). 
It is important for the psychiatrist to be thoroughly familiar with the 
characteristic features of neurological disorders with varied or complex 
manifestations in order not to misdiagnose some of these conditions as 
tardive dyskinesia (Granacher,1981). 
2.1.3 Pathophysiology and aetiology 
While the dyskinesia-dystonia disorders constitute reasonably well 
delineated clinical entities, the mechanisms in anatomical, physiological 
and biochemical terms s^re in the majority of cases far from well 
elucidated. Of such disorders, Parkinson's disease is historically one of 
the best documented and merits some detailed consideration since the 
underlying neurochemical disturbance may be viewed as a prototype model 
for the understanding of movement disorders in general. 
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The most commonly encountered form of Parkinson's disease is 'idiopathic 
parkinsonism' or 'paralysis agitans' as described originally by James 
Parkinson in 1817. The cardinal neurological deficits comprising this 
condition are tremor, muscular rigidity, hypokinesia and postural 
abnormality. 
A similar constellation of neurological signs was a common aftermath of 
the pandemic of von Econmo's disease (encephalitis lethargica or epidemic 
encephalitis) at the close of the Sreat War. Cases could appear up to 20 
years after the original infection which was sometimes extremely mild. 
The onset of the 'post-encephalitic' variety was usually at an earlier 
age than the 'idiopathic' type and the former presented clinical features 
(such as oculogyric crises and abnormal pupillary responses) not 
encountered in the latter type. 
Dther conditions that damage the basal ganglia, as well as causing 
diffuse brain damage, and result in an akinetic-rigid syndrome include 
repeated head injuries (such as the punch-drunk syndrome), cerebral 
syphilis, cerebral anoxia, carbon monoxide poisoning and manganese 
toxicity. Of particular relevance is the fact that a Parkinsonian 
syndrome can be induced by certain medications, and in addition such a 
syndrome may appear as part of other degenerative disorders such as 
Alzheimer's disease, Wilson's disease or cerebral arteriosclerosis. The 
latter, however, is no longer recognised as a cause of Parkinson's 
disease per se and the category of 'arteriosclerotic parkinsonism' 
has fallen into disrepute. 'Idiopathic parkinsonism' is usually diagnosed 
when no evidence can be found from the history and examination for the 
presence of other diseases which could be aetioloqically relevant. 
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Parkinsonism is associated with lesions in component parts of the 
extrapyramidal motor system, especially the pigmented nuclei of the brain 
stem. It is now widely accepted that the substantia nigra of the midbrain 
is an essential site of origin for the disorder. Histological cellular 
degeneration affects the globus pallidus, putamen, caudate and associated 
nuclei and is a constant feature in the zona compacta of the substantia 
nigra (Greenfield,1963). The melanin-bearing cells of the substantia 
nigra are particularly affected to a degree that may be visible to the 
naked eye. In contrast to the cellular changes tract lesions are slight, 
and scattered nonspecific changes may be found in the diencephalon, 
brainstem, cord and cerebral cortex. In post-encephalitic parkinsonism 
the pigmented cells of the substantia nigra and locus coeruleus are 
similarly lost. 
Of major significance in the understanding of the biochemical basis for 
parkinsonism has been the establishment of a fundamental neurotransmitter 
disturbance in the affected basal ganglia - the idiopathic disease 
consequently can be viewed as a specific degeneration affecting one cell 
system namely the melanin pigmented neurones of the brainstem which 
synthesise the catecholamine neurotransmitters dopamine and noradrenaline 
(Parkes and Marsden,1973). Dopamine (DA) is normally found in high 
concentration in the pigmented cells of the substantia nigra, the 
nigro-striatal tract and its terminals in the caudate and putamen. DA 
concentrations are greatly reduced in the brains of most parkinsonian 
cases, idiopathic and post-encephalitic, sometimes being reduced to 107. 
of the normal level in the striatum. Such reductions are evidently due to 
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degeneration of dopaminergic fibres connecting substantia nigra with 
striatum - the nigro-striatal tract (Hornykiewics,1971). Available 
evidence supports the hypothesis that DA and acetylcholine (ACH) act 
antagonistically in their effects on the striatum and any alteration of 
the DA-ACH balance which favours cholinergic dominance results in 
parkinsonism. Further evidence tending to support the concept of DA lack 
as being fundamental in the genesis of this disorder is the finding of 
low homovanillic acid levels in the cerebrospinal fluid of untreated 
patients with parkinsonism - homovanillic acid is the endproduct 
catabolite of DA metabolism, and its diminution in the cerebrospinal 
fluid has been cited as a confirmatory test for idiopathic parkinsonism. 
The successful use of anticholinergic drugs, levodopa and dopamine 
agonists in the treatment of parkinsonism represents practical 
exploitation of the biochemical research findings and additional direct 
confirmation of the postulated neurotransmitter dysfunction. 
Research in the field of the other movement disorders has been less 
decisive in providing biochemical rationale far observed clinical 
phenomena and in many instances neither the exact aetiology, anatomical 
location nor the underlying pathophysiology have been established. 
However in those conditions manifesting gross dystonic or choreo-athetoid 
features, degeneration of the basal ganglia has been documented at both 
macroscopic and microscopic levels thus suggesting neurotransmitter 
imbalance as a final common pathway in the evolution of the total 
clinical presentation. 
Huntington's chorea is characterised by dementia associated with movement 
disorders of varying severity; not unexpectedly the brain is usually 
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small and atrophic with morbid changes frequently most emphasised in the 
•frontal lobes. Grossly there is marked dilatation of the ventricular 
system, especially of the frontal horns, with striking shrinkage of the 
heads of the caudate nuclei (which instead of bulging into the lateral 
ventricles atrophy into a rim of tissue along the ventrolateral edge of 
the dilated anterior horns). Similar neuronal loss is seen in the putamen 
while the globus pallidus may be spared to a large degree. The 
microscopic picture is one of cell loss with gliosis in the cortex 
(especially layers 3, 5 and 6 of the frontal and parietal lobes) with 
striking small cell disappearance from the caudate and putamen. Less 
severe changes are sometimes found in the globus pallidus, substantia 
nigra or cerebellar nuclei. The aetiology of this clearly genetically 
determined condition is unknown although the dominant inheritance is 
suggestive of an inborn error of metadolism possibly derived from 
abnormality in a specific enzyme process controlled by a single qene. 
Studies on autopsy brain material indicate a reduced gamma aminooutyric 
acid (GABA) level in the basal ganglia (Perry et al,1973) while a marked 
reduction of the enzyme responsible for GABA synthesis (glutamic acid 
decarboxylase) has been noted in the putamen and globus pallidus (Bird 
and Iverson,1974). GABA is known to be an inhibitory synaptic transmitter 
and an imbalance between GABA and DA in the striatal and other areas 
could be the basis of at least the movement disorder component of 
Huntington's chorea. A more recent review on the role of DA in relation 
to this condition based upon postmortem brain examination has been 
provided by Spokes (1979). A further interesting finding is a loss of 
Substance-P, an undecapeptide, from the substantia nigra and internal 
segment.of the globus pallidus; Substance-P is considered to be an 
excitatory neurotransmitter in the nervous system (Kanazawa et al,1979.>. 
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By contrast with the marked overall brain atrophy of Huntington's chorea, 
the external appearance of the brain in Wilson's disease is usually 
normal. On section however the corpus striatum is found to be shrunken 
and brownish or brick red in colour and the putamen often shows 
cavitation. Microscopically neuronal loss is evident in the caudate and 
putamen while the globus pallidus may manifest little pathology. 
Abnormalities of copper metabolism appear to be fundamental in the 
development of the ceredral lesions as well as the multinodular cirrhosis 
which characterises this disease thereby providing the designation 
hepato-lenticular degeneration. The resulting neurological disorder is 
confined to the motor system taking the form of extrapyramidal 
disturbance with rigidity, tremor, athetoid writhing movements and 
abnormal dystonic postures of the limbs. From the psychiatric aspect the 
neurological disturbance in the early stages of the disease may be 
transient and sensitive to emotional influences leading to an erroneous 
impression of conversion hysteria. The exact pathogenesis of the disorder 
remains uncertain but is closely related to an associated deficit of 
ceruloplasmin (Scheinberg and Gitlin,1952) which is a feature of great 
diagnostic importance. Both the clinical features and the anatomical 
location of the brain lesions strongly suggest that the movement 
disturbances originate from a background neurotransmitter imbalance not 
dissimilar from that of both parkinsonism and Huntington's chorea, 
however direct experimental evidence in support of such a postulate is 
lacking. 
Ball ism is a movement disorder seldom encountered by the psychiatrist, 
the clinical features of which differ radically from the disorders 
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already mentioned. It is a violent species of chorea and the sufferer is 
afflicted with gross flinging movements of the extremities particularly 
the arms. The abnormal movement is usually unilateral - hemiballismus -
and follows a contralateral lesion in or near the subthalamic nucleus of 
Luys. The syndrome can be simulated by experimental lesions in primates 
which can, as in man, be relieved by a secondary lesion in the pallidum, 
thalamus or upper motor neurone system. Detail of the basic 
pathophysiological mechanism is unknown. 
Lack of knowledge concerning fundamental neuropathology underlying other 
tremors, tics, habit spasms and dystonias is reflected by the generally 
disappointing forms of therapy currently employed in their clinical 
management. As previously mentioned several of these conditions have been 
considered to be substantially of emotional origin and labelled as 
hysterical features requiring psychiatric modes of treatment. While 
psychodynamic factors may indeed represent a not insignificant component 
of the clinical picture in many instances, an underlying DA 
neurotransmitter dysfunction can be inferred from the fact that many of 
the drugs proven in any way therapeutically beneficial sre established 
DA-receptor blocking agents. 
2.1.4 Schizophrenic hyperkinesia 
Erratic and abnormal movements in the form of stereotypies and mannerisms 
have been classically presented by schizophrenic patients. 
In 1907 Kraepelin described 'a type of convulsive movement, involving the 
17 
muscles of eye and speech, which is both characteristic and of frequent 
occurrence in dementia praecox'". He wrote "These movements remind one of 
choreic movements and are quite independent of ideas and feelings. There 
may be associated with them smacking of the lips, clucking the tongue, 
sudden grunting, sniffing and coughing. Furthermore, in the lips we 
observe very rapid rhythmical movements. More often there exists a 
peculiar choreiform movement of the mouth which may be described as an 
athetoid ataxia" (Kraepelin,1907). 
Later, in 1911, Bleuler observed "grimaces of all kinds, peculiar ways of 
shrugging the shoulder, extraordinary movements of the tongue and lips" 
(Bleuler,1911). 
A more recent thorough study of abnormal motility in a long term hospital 
population reported mainly repetitive, semi voluntary movements and 
rituals (Jones and Hunter,1969), although choreiform movements have also 
been documented as accompanying the classical mannerisms and stereotypies 
of schizophrenia (Yarden and Di Scipio,1971). 
These repetitive actions documented in unmedicated schisophrenic patients 
may in many respects closely resemble the involuntary movements of the 
disorders already discussed, however there is no evidence at present to 
indicate that schizophrenic dyskinesia of this type emanates from organic 
disturbance of the basal ganglia. 
2.1.5 Drug induced hyperkinesias 
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Until 1968 treatment of parkinsonism relied upon the use of 
anticholinergic drugs based on atropine derivatives. Within the first few 
years of the introduction of L-dopa an enormous range of side effects 
were reported including involuntary movements of choreiform type and 
every described variety of dyskinesia, akathisia, ballistic, myoclonic 
and facial movement. Such clinical responses reflect the effect of DA 
excess at the dopaminergic post-synaptic receptor sites and would be 
predictable by the proposed neurotransmitter imbalance underlying basal 
ganglia dysfunction. 
A clinical picture identical to Sydenham's chorea has been recognised as 
being provoked in certain women by the use of birth control pills, and 
similar features have occasionally resulted from administration of 
anabolic steroids. Metoclopromide (Maxolon), in popular use for 
gastrointestinal spasm and flatulence, is a drug of the substituted 
benzamide group which can produce tremors and parkinsonian features Undo 
and Ando, 1932) as well as dystonic reactions (Lavy et al,197S) and 
tardive dyskinesia (Wiholm et al,1984); sulpiride (Eglonyl) is another of 
this drug group that has recently been reported to produce parkinsonism 
(Quinn and Marsden,1984). Rarely thyroid hormone may induce hyperkinetic 
movements (Klawans and Shenker,1972). 
Of particular interest and importance to the psychiatrist are the varied 
movement disorders produced by many psychotherapeutic drugs (Roos and 
Buruma,1983). Such agents include anticonvulsants (carbamazepine and 
phenytoin), stimulants (amphetamine and related substances), 
antidepressants (some weakly 'atropinic' tricyclics), major 
tranquillisers (especially the phenothiazine, thio;-:anthene and 
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butyrophenone derivatives) and drugs used in the control of mania 
(lithium and reserpine). Reserpine, which is also employed in the 
treatment of hypertension, causes a parkinsonian syndrome at doses lower 
than any of the other drugs already mentioned. The neurochemical 
disturbances underlying the iatrogenic dyskinetic effects produced by 
some of these substances will be amplified in the following section. 
2.2 DYSKINESIA - NEUROCHEMICAL PERSPECTIVE 
2.2.1 Neural transmission 
The basic functional unit of the nervous system is the nerve cell which 
transmits electrochemical excitation through its specialised 
microstructure to other neurones. Structurally the nerve ceil comprises a 
body with two principal extensions viz. numerous dendrites that receive 
information via receptors, and an axone wnich transmits messages to the 
presynaptic terminal. A narrow gap, the synaptic cleft, separates two 
neurones at a transmission point known as the synapse. Neurotransmitter 
chemical sustances are released from the presynaptic nerve axone 
terminal, diffuse along the concentration gradient across the cleft and 
combine with postsynaptic receptor sites on the dendrites of the 
postsynaptic neurone. Neurotransmitters are thus chemical moeities which 
facilitate the transmission of electrical potentials between neurones -
such stimuli may be either excitatory or inhibitory in character - and 
researchers estimate that only some 57. of the brain's neurotransmitters 
have been identified. Some of these chemical substances may function 
somewhat differently and are thought to affect neurons in a normone-iike 
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way rather than by transferring the nerve signal from the pre- to the 
postsynaptic element: the term 'neuromodulator' has been appended to this 
type o-f neuroregulator, and the criteria far distiguishing between 
neuromodulators and neurotransmitters has been given by Barchas (Barchas 
et al,1978>. Of the several neurotransmitters already identified, the 
biogenic amines are considered to have particular relevance to the 
clinical problem of movement disorders and have been implicated in the 
production of psychotic mental disturbance including schizophrenia (Smith 
and Copolav,1979). 
2.2.2 Catecholamines : noradrenaline 
Noradrenaline (NA) - also termed norepinephrine - is a principal amine 
transmitter substance in both the central nervous system and the 
postganglionic fibres of the peripheral sympathetic nervous system, and 
is also released from the adrenal medulla. 
Most noradrenergic neurones originate in the brainstem from the locus 
coeruleus and tegmental nuclei of the pons and medulla. This is the zone 
wherein the cell bodies are located and from which two main neuronal 
tracts - dorsal and ventral - are derived. The dorsal bundle arising in 
the pons spreads caudally and terminates diffusely in the neocortex, 
limbic system, hippocampus, cerebellum, thalamus and dorsal hypothalamus. 
The ventral tract is of more limited distrioution travelling trom the 
pons to the hypothalamus and limoic system. 
Receptors for NA are classified as alpha or beta depending on drug 
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affinity; the postsynaptic or alpha-1 receptor is stimulated by 
adrenaline, noradrenaline and phenylephrine and blocked by phentolamine; 
the presynaptic alpha-2 receptor acts in an autoreceptor capacity 
providing feedback inhibition on the release of NA at the presynaptic 
terminal; beta receptors are most sensitive to adrenalin and 
isoproterenol, being blocked by propanolol. The exact biological 
interrelationships of these receptors has not been completely elucidated. 
2.2.3 Catecholamines : dopamine 
Neurotransmission via DA occurs principally in the central nervous system 
although it may also take place at some sites in the autonomic nervous 
system. Synthesis of this amine follows essentially the same chemical 
intermediate pathway as for NA, however DA neurones lack the enzyme 
dopamine hydroxylase which converts DA -> NA. 
Within the central nervous system five DA sub-systems, showing a high 
degree of topographic organisation, have been identified. The main 
extrapyramidal pathway begins in the substantia nigra of the midbrain and 
ends in the caudate nucleus and putamen of the basal ganglia; this 
pathway is specifically involved in control of movement but may have 
additional cognitive functions. Midbrain to forebrain (from the A10 area 
medial to the substantia nigra innervating the nucleus accumoens and 
related nuclei including the olfactory tubercle and an area of frontai 
cortex) connections of the mesolimbic tracts appear to be involved in 
memory and emotion; it has been suggested (Crow et al,l?77) that the 
nucleus accumbens is the site of action of antipsychotic drugs. Tracts of 
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more restricted distribution are the tuberoinfundibular system which 
connects the hypothalamus to the pituitary -for control of the 
hypothalamic-pituitary endocrine system, the incertohypophyseal tract and 
the periventricular tract (Bjorklund,197S). 
The neuroanatomical organisation o-f t"ibre tracts interconnecting the 
'pyramidal' and 'extrapyramidal' brain systems is exceedingly intricate 
and complex, and the striatum itself can be functionally divided into 
'ventral' and 'dorsal' or 'limbic' and 'non-limbic' moeities 
(Scheel-Kruger and Arnt,1985). The pharmacology of the DA receptors found 
within brain regions innervated by fibres arising in the 'ventral' 
striatum differs considerably from that of the DA receptors arising in 
the 'dorsal' striatum - the former receptors are stimulated by 
apomorphine and inhibited by neuroleptics such as haloperidol (D2 
receptors), while the latter mesolimbic receptors are stimulated by 
clonidine-like drugs and inhibited by agents such as ergometrine and 
piribedil (Nieuwenhuys and Cools,1933). 
Currently DA receptors are classified into D-l and D-2 types, and 
functionally into either high and low affinity forms (Seeman,1985). The 
farmer receptor is linked to the adenylate cyclase system while the D-2 
type is not. Drugs which act as D-l receptor antagonists include the 
phenothiazines and piribedil, while pimozide, the phenothiazines, 
butyrophenones (relatively selective) and substituted benzamides 
(absolutely selective) act on the latter. It is the D-2 receptor that is 
implicated in the neuroendocrine control of growth hormone and prolactin, 
the movement disorder of drug-induced parkinsonism and the antipsychotic 
action of DA antagonists. 
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2.3 NEUROLEPTIC DRUGS 
2.3.1 Mode of action 
The current state of knowledge concerning amine receptors and the effects 
of antipsychotic medication stems from introduction by Delay and Deniker 
(Delay et al,1952) in the early fifties of the drug chlorpromazine as a 
specific treatment for psychotic patients. The antipsychotic application 
of this compound evolved on purely empirical grounds since the original 
chemical structure resulted from a systematic search for a phenothiazine 
with stronger central actions than the antihistamine promethazine, and 
chlorpromazine was first used in an analgesic mixture; its potentially 
advantageous application to psychiatry was quickly exploited so that by 
1954 the efficacy of this halogenated promazine derivative in the 
treatment of schizophrenia was well established (Swazey,1974). At about 
the same time reserpine, an extract of Rauwoifia, had also been 
demonstrated to have antipsychotic effects but its clinical use was 
rapidly superseded by chlorpromazine (Miner,1955). Following the 
therapeutic success of chlorpromazine, other neuroleptics were 
synthesised by chemical substitutions either of the side chain (position 
10) or the ring (position 2) of the basic phenothiazine nucleus. Although 
their mechanism of action was not understood, it had however been 
suggested (Deniker,1960) that the antipsychotic effects of neuroleptic 
drugs was related to the tendency of these drugs to induce extrapyramidal 
effects. The principal argument against this view was that certain 
compounds - such as thioridazine - have a lesser incidence of 
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parkinsonian effects than chlorpramazine (the accepted standard 
phenothiazine), although nonetheless manifesting unequivocal clincial 
therapeutic activity. It has subsequently become apparent that 
extrapyramidal effects of antipsychotics may be inversely proportional to 
their affinity for central muscarinic receptors, thus a drug such as 
thioridazine may have enough intrinsic anticholinergic effect to 
compensate for its disturbance of the extrapyramidal balance between 
dopamine and acetyl choline (Snyder et al,1974). 
The further introduction of antipsychotic drugs, some chemically closely 
related to phenothiazines (such as the thioxanthenes) and others of quite 
different structure (such as the butyrophenones), have tended to confirm 
the conjecture that extramidal and antipsychotic effects are closely 
related and reflect a basic commonality of pharmacolgical action in these 
compounds. Recalling the findings of Hornykiewicz (1973) mentioned 
earlier, viz. lowered brain basal ganglia DA concentrations in patients 
with Parkinson's disease, it is reasonable to assume that the 
parkinson-like extrapyramidal manifestations (and even the antipsychotic 
effects) of neuroleptic drugs are a consequence of functional 
interference with DA systems in similiar areas of the central nervous 
system. Whilst, however, in Parkinson's disease there is good evidence to 
believe that the impairment of dopaminergic neurotransmission is a likely 
consequence of primary organic degeneration in the nigrostriatal and 
other pathways with a depletion of DA stores, the effect of antipsychotic 
drugs is accomplished apparently without quantitative DA loss. In fact 
antipsychotic medication has been found to actually enhance presynaptic 
DA turnover and increase dopaminergic neuronal firing (Carlsson and 
Lindqvist,1963), a finding which has been interpreted as indicating a 
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•feedback response of presynaptic receptors to blockade of the 
postsynaptic DA receptor sites. Consistent with this view is the fact 
that these drugs can reverse amphetamine induced abnormal mental states 
which are dependent upon central DA release (Randrup and Munkvad,1965). 
Attention was thus focussed on DA receptors and significant progress was 
made with the finding of a DA sensitive enzyme, adenylate cyclase, in 
brain striatal tissue (Kebabian et al,1972). This enzyme is intimately 
bound with a postsynaptic DA receptor site (specifically the D-1 receptor 
as already mentioned above) and its activation by DA is selectively 
antagonised by neuroleptic drugs. Studies of the potencies of a range of 
neuroleptics in antagonising DA stimulation of this enzyme have 
demonstrated that activity in this system is in general closely related 
to antipsychotic potency (Clement-Cormier et al,1974). 
Use of 1igand-binding techniques has also provided information on the 
function of DA receptors. Butyrophenone drugs such as haloperidol and 
spiroperidol bind to striatal tissue in vitro', by means of 
radioactive tritium labels and interactions with other compounds it is 
possible to identify the component of binding associated with the DA 
receptor. Ligand binding is inhibited by the presence of other DA 
antagonists and the relative patencies of various neuroleptics in terms 
of interaction with the DA receptor; thus defined there appears to be a 
positive correlation between DA receptor antagonism and clinical potency 
(Seeman et al,1976). 
To summarise, there is a substantial weight of clinical and experimental 
evidence to indicate that the main action of neuroleptic drugs at the 
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cellular level is one of postsynaptic DA receptor blockade (Berger et 
al,1978) - the more efficient the blockade the higher the antipsychotic 
potency of the drug, and the more likely it is to generate undesirable 
extrapyramidal side-effects as a consequence of hampered DA 
neurotransmitter activity. However as Hornykiewicz (1978) has pointed out 
there are exceptions to this general statement wnich tend to weaken the 
hypothesis that neuroleptic antipsychotic activity is solely due to 
selective blockade of brain DA receptors, while the exact antipsychotic 
mechanism of these drugs has not been elucidated and remains a focus of 
debate, there can be no doubt that their clinical administration produces 
profound DA receptor blockade in the nigrostriatal system (producing 
extrapyramidal motor disturbances) and in the tuberoinfundibular system 
(inhibiting growth hormone release and increasing prolactin release by 
the pituitary). The growing list of drugs manifesting antipsychotic 
properties - some of which have not been exploited commercially because 
of excessive toxicity or other unacceptable effects - make it extremely 
difficult to define some common chemical structure that would explain 
their pharmacological activity and clinical effects. With regard to 
chlorpromazine one attractive suggestion was that the molecule might 
assume a configuration such that a part thereof would fit the 
stereostructure of DA; this would enable chlorpromazine to attach to and 
occupy DA receptors with a subsequent blocking action (Horn and 
Snyder,1971). Although a neat and aesthetically pleasing concept it does 
not seem likely that the newer non-phenothiazine chemical entities will 
follow such a specific categorisation, and no one is sure which of 
several possible configurations any particular molecule will assume. 
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retrocollis). Occasionally there may be involvement o-f the respiratory or 
laryngeal musculature (stridor, dysarthria and -foaming), or the limd and 
axial muscles may be affected producing opisthotonus, tonic -flexions o-f 
the arms or legs and dystonic posture or gait. The sufferer is fully 
conscious and acutely distressed by the involuntary muscle spasms. 
Dystonia of this type develops soon - within hours or the first few days 
- after excessive initial doses or too rapid increments of medication, 
although its appearance may partly depend upon individual sensitivity. It 
reportedly occurs more commonly in men than women and in younger rather 
than older patients (Ayd,1961), and is readily controlled by intravenous 
benzodiazepines or anticholinergic drugs. 
Such reactions occur in some 27. of patients exposed to neuroleptics and 
the exact pathophysiology of this drug response is incompletely 
understood. Similar dystonic effects can be reproduced in animals, and 
bizarre manifestations typical of the syndrome observed in humans have 
been reported in baboons treated with haloperidol (Meldrum et al,1977). 
The findings emanating from experiments on primate models would seem to 
indicate that acute dystonic reactions are produced as a result of 
effects on presynaptic DA mechanisms.Such a response possibly occurs 
via a compensatory DA synthesis and release provoked by acute 
administration of neuroleptic drugs, being a physiological attempt by DA 
neurones to overcome postsynaptic neuroleptic DA receptor blockade 
(which per se stimulates a heightened postsynaptic DA receptor 
sensitivity, termed 'super-sensitivity'). 
2.3.2.2 Akathisia 
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A significant pharmacological effect of neuroleptics in both animals and 
man is tranquillisation producing mental quiet and motor immobility. 
Akathisia therefore represents a distinctly paradoxical sequela of 
neuroleptic treatment, being a peculiar state of mental and motor 
restlessness characterised by intense desire to move in order to gain 
relief from overwhelming feelings of distress. 
Akathisia and drug induced parkinsonism commonly co-exist and it has been 
suggested that the former is a consequence of postsynaptic DA receptor 
blockade in cerebral DA containing areas other than the carpus striatum. 
Thus while blockade of receptors in the striatum and such mesolimbic 
areas as the nucleus accumbens produces inhibition of locomotion in the 
form of akinesia and catalepsy, the reverse occurs on blockade of 
mesocortical DA systems. In rodents, destruction of the mesocortical 
pathways or their terminal projection areas in the mediofrontal and 
cingulate areas causes locomotor hyperactivity; although entirely 
speculative it is conceivable that blockade of DA receptors in specific 
cortical areas of the human brain could produce the physical and mental 
manifestations of akathisia. 
2.3.2.3 Parkinsonism 
As previously mentioned iatrogenically induced parkinsonism - also called 
'pseudoparkinsonism' or 'Parkinson-like syndrome' - comprises the classic 
Parkinson triad of hypokinesia, rigidity and tremor which may be 
accompanied by postural abnormalities and hypersalivation. The 'akinetic 
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syndrome'' consisting of hypokinesia or bradykinesia isthe primary and 
sometimes only symptom, being manifested clinically by a lack of facial 
expression, micrographia, loss of accessory body movements, monotonous 
speech and slowness in initiating motor actions; voluntary movement is 
reduced and the patient may complain of muscular weakness and fatigue. 
Drug induced parkinsonism presents some 2 to 4 weeks after instituting 
therapy and usually spontaneously diminishes in intensity without 
reduction of medication. It has been reported (Gerlach et ai,1977) that 
after 3 months of neuroleptic treatment at most 257. of the patients 
require treatment with anticholinergic antiparkinsonian drugs. After 
withdrawal of neuroleptics the condition remits in the course of a few 
days or weeks, but in a few cases (Marsden and Jenner,1930) it may 
persist for several months or even become irreversible. Low dose 
neuroleptics and perhaps depot preparations in particular are more liable 
to elicit parkinsonism than high dose neuroleptics, possibly due to the 
high intrinsic anticholinergic effect of the latter. 
Broadly speaking drug induced parkinsonism is a dose dependent 
phenomenon, however in routine clinical use only some 207.-407. of patients 
develop overt manifestations and it would appear that an individual 
susceptibility to antipsychotic medication exists, although the factors 
determining such susceptibility nave not been elucidated. The fact that 
the age incidence of drug induced parkinsonism parallels that of the 
idiopathic disease (Ayd,1961) strongly hints that a propensity to the 
latter may determine the incidence of the former. 
From the foregoing statements on the pharmacologic action of neuroleptic 
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drugs it seems reasonable to conclude that a block of cerebral DA 
receptors producing the equivalent of brain DA deficiency is responsible 
for iatrogenic parkinsonism (Hornykiewicz,1975). 
2.3,2.4 Chronic tardive dyskinesia 
Of all the extrapyramidal complications of neuroleptic treatment the 
entity today commonly termed tardive dyskinesia (TD) is potentially the 
most serious since the abnormal hyperkinetic movements may appear only 
after months or years of drug treatment and are not always remediable. 
Moreover the clinical onset of TD can supervene for the first time wnen 
the offending neuroleptic is stopped and it has been postulated that this 
complication may be permanent despite drug withdrawal (Crane,1973). 
Further aspects of this formidable syndrome will be considered at some 
length in the following section, however it would be appropriate at this 
point to add that TD is currently believed to result from a gradual 
disappearance of DA receptor blockade by neuroleptic drugs in the 
striatum and the emergence of striatal DA receptor supersensitivity, 
despite continuation of drug intake. That this is undoubtedly an 
oversimplified concept is borne out by the clinical finding that TD and 
parkinsonism not infrequently may coexist in the same subject 
(Gerlach,1977, Mukherjee et ai,1982), an observation difficult to explain 
solely on the basis of DA receptor dysfunction witnout consideration of 
cholinergic-dopaminergic imbalances. Clinical testing of cholinergic 
agents and drugs which facilitate or inhibit acetylcholine have shown 
that only some 507. of patients with TD respond in a fashion fitting tne 
cholinergic-dopaminergic imbalance theory, suggesting that TD is not a 
pathophysiological^ homogeneous entity (Moore and Bowers,1980). In 
addition the importance o-f central noradrenergic mechanisms in the 
regulation of locomotor activity cannot be ignored, since it has been 
proposed that NA sets up the sensitivity of the neural systems upon which 
DA acts and thus controls locomotion (Hornykiewicz,1976). In this context 
it is worth noting that although 'typical''' neuroleptics are generally 
believed to be specific DA receptor blockers (Hyttel et al,1985>, there 
is evidence to implicate a blockade of beta-noradrenergic receptors as 
one of the major pharmacologic effects of these drugs (Sternberg et 
al,1981). Some direct clinical data suggesting adrenergic system 
involvement has been the recent finding of elevated cerebrospinal fluid 
NA levels in TD patients (Jeste et al,1984), together with earlier 
documentation of elevated plasma dopa-beta-hydroxylase and renin 
activities in a subgroup of TD cases (Jeste et al,1982). Further studies 
are necessary to clarify the relationship between TD and adrenergic 
neural systems in the brain, 
2.4 TARDIVE DYSKINESIA 
2.4.1 Neurological syndromes 
The clinical value of neuroleptic drugs lies in their aDility to induce a 
state of tranquility without concomitant clouding of consciousness, a 
quality which has established these compounds as the mainstay of 
management of acute toxic confusional and psychotic mental states. The 
longer term use of neuroleptics has been advocated for the control of 
chronic schizophrenic thought disorder and the prevention of acute 
relapses in schisophrenic outpatients (Hogarty and Ulrich,1977). Their 
widespread therapeutic application was closely associated with 
neurological side effects which appear to be intimately bound with and 
indeed may even parallel antipsychotic potency. Within the first few 
years of clinical usage there were a variety of reports indicating 
dystonic attacks and parkinsonism as complications presenting in the 
early phases of treatment, while an involuntary hyperkinesia was 
recognised as a later phenomenon (Berger and Rexroth,1980). This delayed 
hyperkinetic syndrome was termed •'tardive dyskinesia' (Faurbye et 
al,1964) to signify a movement disorder that could manifest itself and 
persist for years, even after the discontinuation of treatment with the 
precipitating agent. The term TD has become generally accepted and 
recognised, although other designations have been used in the past to 
describe this condition including 'terminal extrapyramidal insufficiency 
syndrome', 'persistent extrapyramidal hyperkinesia' and 'complex 
dyskinesia' (Gerlach,1979). As will become evident later, TD thus 
represents a rather loosely defined clinical entity which is empirically 
related to usage of drugs which block DA receptors in the central nervous 
system. Some of the abnormal involuntary movements of TD are very like 
those encountered in other forms of dyskinesia produced by specific 
disease processes involving the basal ganglia already described. It is 
probably for this reason, at least in part, that studies attempting to 
define predisposing, precipitating and perpetuating factors in relation 
to TD have yielded inconclusive, varied and often conflicting findings. 
Currently doubt has been voiced concerning the use of the term TD to 
describe involuntary movements of different patterns and unpredictable 
response to medication (Kidger et al,1980), and there is a body of 
opinion favouring the view that TD represents a heterogenous group of 
disorders with a variety o-f anatomical, neuropathological and 
pathophysiological bases (Baldessarini et al,l?80). 
The original early characterisation o-f TD was that o-f involuntary 
hyperkinetic movements varying in localisation and appearance but 
occurring with most emphasis in the mouth area, the so-called 'bucco -
linguo - masticatory syndrome' triad or 'oral dyskinesia' (Uhrbrand and 
Faurbye, 1960). The circumoral muscles with those o-f the jaw and tongue 
were involved producing complex movements, typically sucking, chewing and 
lateral jaw actions, thrusting and writhing o-f the tongue, and smacking 
or pursing o-f the lips. Tic-like motions o-f the lips might also spread to 
involve the eyes and eyebrows resulting in erratic grimacing (an 
oro-facial syndrome). The pattern of movements di-f-fer -from individual to 
individual but tend to show constancy o-f distribution although varying in 
intensity at different times. It has been stated that in younger patients 
the movements frequently consist of regular relatively simple tongue 
protrusions with synchronous jaw movements, while in older persons the 
movements are more complex and irregular, the tongue rotating and licking 
in all directions both inside and outside the mouth. Persistent oral 
dyskinesia can result in hypertrophy of lip and tongue musculature with 
coarsening of the features. 
As the condition was studied more the mouthing movements were further 
refined to include puckering, panting, smacking and tongue movements 
inside the mouth, and the syndrome of TD was broadened from oro-facial 
dyskinesias to include choreoathetoid movements of the head, neck, trunk 
and limbs (Table I). Furthermore the clinical picture was complicated in 
some cases by difficulties of speech and swallowing and by irregular 
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respiration due to disturbed diaphragmatic action. Thus a wide diversity 
of abnormalities have been documented under the rubric of TD including 
axial dystonias, flinging or ballistic-type movements particularly of the 
arms, movements of fingers and toes, shoulder shrugging, rotatory pelvic 
movements and lordosis (Marsden et al,1975, Baldessarini and Tarsy,1978, 
Klawans et al,1980). 
In general the movements of TD are exacerbated with anxiety and on 
distraction of attention, volitional motor activity or with any attempts 
to voluntarily control the dyskinesia. Relaxation or sedation will tend 
to decrease the dyskinetic symptoms and the movements disappear during 
sleep. 
The early stereotype of a typical candidate for the development of TD was 
an old, brain damaged woman who had been hospitalised for a number of 
years and had received large doses of medication. This depiction is far 
from accurate and TD is now known to occur with noticeable frequency in 
younger patients, non-brain-damaged subjects and non-psychotic patients 
who have received neuroleptics. 
2.4.2 Variants 
Reported drug induced phenomena include syndromes resembling Huntington's 
chorea, dystonia musculorum deformans, various tics, and other 
degenerative diseases of the basal ganglia (Crane,1973). Retrocollis has 
been described as an irreversible and fatal complication of neuroleptics 
in old patients (Harenko,1967), while permanent torticollis has been 
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reported -following neuroleptic overdosage (Angle and Mclntire,1968) and 
an entity termed 'psychopharmacotoxic encephalopathy' has also been 
attributed to drugs (Grahmann,1967). Such neurological disturbances 
seldom closely mimic the orofacial dyskinetic -features o-f TD. There are 
no established or universally accepted criteria -for the diagnosis o-f TD 
and a number of neuromedical disorders producing a similar clinical 
picture have been described which, if not atypical TD variants, may be 
incorrectly identified as TD (Berger and Rexroth,1980) and thus require 
brief attention. 
2.4.2.1 Spontaneous orofacial dyskinesia 
Alternatively termed 'senile dyskinesia', this entity is clinically 
indistinguishable from neuroleptic induced TD. It has been difficult to 
arrive at an accurate assessment of the prevalence of spontaneous 
dyskinesia, and estimates have been based on studies comparing dyskinesia 
occurring in treated and untreated patient samples, yielding figures 
ranging from 0"/.-367. (Kane and Smith, 1982). Some of the highest figures 
were reported in groups manifesting dementia or 'organic disorder' thus 
implicating neurological pathology partly as the basis of the dyskinesia. 
In Kane's pooled data analysis the average prevalence among 19 untreated 
samples involving 11,000 cases was calculated as 5"/.. 
2.4.2.2 Orofaciocervical dystonia 
Another movement disorder frequently involving buccal musculature as well 
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as causing tremor, chorea and torticollis, is orofaciocervical dystonia 
or the 'Meige Syndrome' (Tolosa, 1979) which was -first described in 1910. 
It is distinguished from other facial spasms or tics by unusually 
bilaterally symmetrical spasms with a predominantly median focus. 
Symptoms may occur without specific cause (the idiopathic variety) or in 
combination with a well defined neurological disorder in patients with 
levodopa or neuroleptic induced dyskinesias (the symptomatic type). 
Thorough neurological examination should permit the clinician to 
distinguish this rare condition from TD. 
2.4.2.3 Rabbit syndrome 
This late onset neuroleptic induced extrapyramidal syndrome is 
characterised by rhythmic involuntary movements of the masticatory 
musculature at the rate of some 5-5.5 per second, which resemble the 
chewing movements of a rabbit (Villeneuve et al,1973). Unlike TD, the 
rabbit syndrome responds to anticholinergics, reverses readily fallowing 
neuroleptic withdrawal and also persists in Stage-I sleep. 
2.4.2.4 Pisa syndrome 
First documented in 1972 as a complication of butyrophenone 
administration (Ekbom et al,1972) this unusual condition has received 
little mention in literature on the side effects of drug treatment, 
however 2 cases have recently been reported following the use of 
chlorpromazine and fluphenazine (Yassa,1984). The clinical presentation 
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consists of a tonic flexion of the trunk to one side, accompanied by its 
slight rotation, in the absence of other concomitant dystonic features. 
Since it occurs in patients receiving antipsychotic medication for 
prolonged periods it may be considered as a manifestation of 'tardive 
dystonia', in contrast with acute dystonic reactions usually appearing in 
the early stages of treatment. Unlike the conditions already mentioned, 
the Pisa Syndrome does not involve the face and so presents no problems 
in the diagnosis of TD, however the combination of TD and dystonic 
symptoms has been described and is impossible to differentiate especially 
when the oromandibular region is affected. The fact that tardive dystonia 
is late in onset, protracted in duration and refractory to therapy 
suggests an aetiological and pathophysiological relationship to TD. 
2.4.2.5 Brueghel's syndrome 
The syndrome of blepharospasm-oromandibular dystonia (Marsden,1976). This 
entity has many features of the Meige syndrome and is considered by some 
authorities to be a variant of orofaciocervical dystonia. 
2.4.2.6 Tardive Tourette syndrome 
This unusual condition was first described in a young woman soon after 
discontinuation of long term neuroleptic treatment (Klawans et al,l978). 
The symptoms consisted of multifocal facial tics spreading to shoulders 
and arms, followed after a few months by vocalisations and barking 
sounds. After this original report several other cases have been 
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described, mostly a-fter long term treatment or after diminution of 
neuroleptic drugs (Mueller and Aminoff,1982). 
2.4.2.7 Tardive akathisia and pseudoakathisia 
Restless or -fidgety movements o-f the limds and trunk, termed 'late onset 
akathisia', have been described as occurring a-fter chronic treatment with 
neuroleptics (Simpson,1977). Subjective symptoms were less apparent and 
the condition was regarded difficult to treat being also frequently 
associated with TD. It has subsequently been suggested (Munetz and 
Cornes,1982) that there may be a positive association between the 
occurrence of akathisia and TD, and also that some akathisia may actually 
be TD, or some form fruste of TD called 'pseudoakathisia'. There could be 
a progression from true akathisia through pseudoakathisia and finally to 
clear cut TD. 
2.4.3 Prevalence rates 
While acute dyskinesia had been recognised early in the usage of 
neuroleptics, with the exception of two brief reports - one berman and 
the other French - TD was not described during the 1950's, and up to 1965 
only three epidemiological studies had appeared in the literature. 
The bulk of the epidemiological data appearing in all major scientific 
publications up to 1980 has been analysed in three comprehensive pooled 
literature surveys, the period 1967-71 by Crane (1973) and the years 
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1959-79 and 1960-80 by Kane and Smith (1982) and Jeste and Wyatt (1981) 
respectively. These critiques merit detailed examination since they 
provide insights into the rationale for inconsistent findings that have 
appeared in the journals, and so provide guidelines for design of more 
reliable clinical investigations. It has become evident that multiple 
causative factors - of which the definition of the syndrome, the type of 
patient population, the methods used in obtaining information and the 
clinical assessment of symptoms, play a major role - contribute variably 
in many of the discrepancies. 
In the reviews mentioned above, TD prevalence figures vary from a low 
0.57. to a maximum of 56.47. and sample sizes (N) of individual studies 
examined range from 30 to 10,000 cases. It is important to note that of 6 
studies involving the largest patient samples (N > 1,000 cases), all but 
1 reflected TD prevalences of 107. or lower. This latter study is also the 
only one of the 6 employing severity scale assessment, possibly yielding 
a more reliable measure of TD. Broadly speaking, higher prevalence rates 
are a characteristic of those studies employing rated severity scales. 
Both Jeste and Kane have provided reasonable statistical evidence 
suggesting an increase in TD over the two decades since 1960. On the 
basis of Jeste's figures (combined data from 36 studies) the overall 
weighted mean prevalence of TD among inpatients rose from some 57. in the 
1960-1965 period, 13.67. until 1970, 23.37. until 1975, to 25.77. during the 
five years 1976 through 1980. Review analysis of 56 studies by Kane 
yielded an average prevalence of 14.67. for 1960 to 1969, while that for 
years 1970-1979 was 23.97. (Kane has used several studies rejected by 
Jeste as being unreliable). 
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These authors contend that their computations represent real increments 
in TD prevalence and are not aberrations due to factors such as 
heightened clinical awareness of the condition, increasing age of 
patients at risk, or concentration of 'sicker' cases in hospitals over 
the past 20 years following return of less disabled individuals into the 
community. Furthermore it is inferred that the positive correlation, over 
the same period, between an increased number of patients receiving long 
term neuroleptic treatment and this rise in prevalence of TD reflects an 
aetiological causal relationship. The conspicuous differences in 
prevalence rates reported in various papers appear to derive from major 
methodological diversities, which require brief individual comment. 
Diagnostic Criteria - Many studies have not defined the symptom clusters 
employed in diagnosing TD, and overinclusive data will thus inflate 
figures of prevalence. As has already been stressed, several neurological 
disorders may present a clinical picture closely similar to TD and it is 
perhaps doubtful if symptoms such as tremors, rigidity and akathisia 
should be identified as TD unless clearly accompanied by the typical 
bucco - lingua - masticatory triad. Problems of this nature are 
exaggerated if TD manifests in the company of a second pathology such as 
paralysis agitans or if cases of senile dyskinesia are not identified. 
Symptom Severity - The adoption of rating scale severity assessment has 
undoubtedly introduced more quantitative and objective appraisal of 
dyskinetic symptoms. Nonetheless the inclusion of cases of borderline or 
mild dyskinesia may result in unrealistically hign prevalence rates and, 
conversely, selection of only severe cases would artificially lower the 
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percentage of patients with dyskinesia. The dramatic effect of this 
variable is exemplified in a large study (Bell and Smith,1973) showing 
that the prevalence of TD in a group of more than 1,300 patients would be 
127. if only severe cases were included, 26"/. if moderately severe cases 
were added and 40% if patients with mild dyskinetic symptoms were 
included. 
Subtypes of Dyskinesia - Studies that treat all TD as a uniform clinical 
entity for statistical purposes may obscure features of significant 
clinical subtypes. Discontinuation of medication sometimes triggers the 
appearance of withdrawal dyskinesia which can ultimately resolve, or in 
fact herald the onset of true TD. Thus at least two clinical forms of TD 
have been proposed, persistent and reversible - remission of dyskinetic 
symptoms within three months of withdrawal of neuroleptics being a 
hallmark of the latter (Jeste et al,1979) which may constitute some third 
of cases manifesting the disorder (Jeste and Wyatt,1979). Surveys done 
soon after cessation of drug therapy could therefore yield a high 
proportion of withdrawal dyskinesias, whereas restricting the diagnosis 
of TD to irreversible cases consequently results in lower estimates of 
the prevalence of the condition. Outpatient group studies are few, 
however as one American publication indicates some 257. to 50"/. of 
individuals may fail to take their medication (Blackwel1,1973), the 
distinction between withdrawal and persistent dyskinesia is an important 
one when computing outpatient prevalence figures. 
Populations Sampled - Prevalence figures are likely influenced by several 
variables dependent upon the patient type included in any particular 
survey, although the degree to which each of these contribute to reported 
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differences is uncertain. Borne studies have been carried out exclusively 
on elderly populations whilst others have included patients o-f one gender 
only. Psychiatric inpatient groups have received most attention and 
outpatients regarded to be at nominal risk -for development of TD, 
although a few surprisingly high outpatient prevalence figures (up to 
407.) have been documented. Primary psychiatric diagnosis cannot be 
correlated with TD which has been reported to occur in patients with 
schizophrenia, dementia and manic-depressive disorders - however, in the 
case of the latter condition, symptoms may fluctuate cyclically possibly 
resulting in variable assessment of severity or prevalence (Holden et 
al,1984). Surveys using older patient groups are likely to include a 
greater proportion of persons with 'brain damage'; early reports 
indicated positive correlation of TD with such damage, which was seldom 
pathologically defined, and at present the contribution of 'brain damage' 
to the development of TD is far from clear, although it may be unwise to 
totally reject organicity as a predisposing element. The role of 
neuroleptics in the genesis of TD is also poorly understood but errors 
might have been reduced by separating neuroleptic treated cases from 
those who had received none or neuroleptics in small amounts for shorter 
periods, a precaution not adopted by most surveys. Studies on Japanese, 
Indian, Turkish, American and other European patients suggest that there 
is no racial predisposition to TD. 
2.4.4 Age and sex prevalence 
It would seem the view that TD is more common among elderly than among 
young patients is generally accepted; several reliable studies comparing 
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patients both with and without TD have shown a higher mean age among the 
•former group. Utilising the -figures from six selected studies Jeste and 
Wyatt (1981) have calculated the weighted mean prevalences in various age 
groups to be 67. at 40 years, 14"/. in 41-50 group, 197. in 51-60 group, 347. 
in 61-70 group and about 317. over 70 years. There appeared to be no 
progressive increase in TD after the age of 70 years although it snould 
be noted that these studies were not prospective longitudinal studies of 
the actual incidence of TD with age. Irreversible TD is rare before the 
age of 40 years and it is possible that irreversibility could be 
accentuated by age related ceredral changes - which per se can 
produce a movement disorder resembling TD, namely senile dyskinesia - and 
hence reflected as a rise in TD with age. 
The work comparing relative prevalence between men and women appears less 
conclusive and findings range from a markedly higher prevalence in 
females to a slightly higher prevalence in males, while others report 
virtually no intersex prevalence differences. Based on a sampling of 19 
studies Jeste and Wyatt (1981) calculated the overall weighted mean 
prevalence in women to be about 417. higher than that in men. At present 
it is unclear whether gender prevalence differences reflect actual 
biological characteristics or simply differences in treatment. One 
interesting unexplained observation (Smith et al,1978) was that women 
showed linear increase in TD prevalence with age, while in men prevalence 
decreased after the age of 70. 
2.4.5 Treatment practices 
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It would be rash to lightly cast aside indications that neuroleptic 
therapy is a major factor influencing prevalence of the TD syndrome. 
However drug type, made and frequency of administration, cumulative druq 
exposure and concomitant use of anticholinergic medication have all been 
examined, but have failed to yield any clear pattern relating these 
variables to the onset of dyskinesia. 
There is no hard evidence that certain types of neuroleptics are more 
likely to produce dyskinesia than others. Kane and Smith (1982) reviewed 
15 studies on drug type and TD prevalence and found 5 which reported 
significant findings. Many of these latter studies tended to relate high 
potency depot fluphenazine to TD but for methodological reasons this 
finding cannot be considered conclusive. 
It has not been possible to relate TD prevalence to maximum daily dose of 
drug administered or cumulative drug dosage despite a widely assumed 
notion that development increases with drug exposure. There are likewise 
no controlled data suggesting any association between neuroleptic 
polypharmacy and an increased risk for the development of TD. 
The observation that anticholinergic agents frequently (though not by any 
means consistently) exacerbate already manifest TD has fostered the 
speculation that the use of such drugs might increase the risk of TD 
development. At present there is, however, insufficient adequate clinical 
data to implicate exposure to anticholinergic agents as a significant 
risk factor in the development of TD. It would nonetheless with the 
present state of knowledge in this area, be unwise to reduce the 
importance of judicious use of anticholinergic medication as an adjunct 
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to long term neuroleptic therapy. 
Given concerns about the risk o-f TD, some have recommended 'drug 
holidays' or more lengthy drug tree intervals as a way o-f reducing the 
liklihood o-f the problem. The data supporting this idea are minimal at 
best, and there is insufficient information to encourage or discourage 
drug free intervals in this context. Drug 'holidays' may be useful in 
identifying patients with masked or latent dyskinesias, but their role in 
increasing or decreasing the risk of TD development is speculative. 
Experimentally it has been shown that intermittent haloperidol treatment 
increased tritiated spiperone binding to the same degree as continuous 
haloperidol therapy (Bannet et al,1980), and at least two studies have 
been reported suggesting that drug free intervals may be related to an 
increased incidence of dyskinesias (Degkwitz et al,1967, Jeste et 
al,1979). Therefore there is a disquieting possibility that 'drug 
holidays' could actually lead to persistent dyskinesia. 
2.4.6 Clinical assessment 
The reliable and reproducible assessment of dyskinetic movements has 
been, and continues to be, a substantial clinical problem. The majority 
of studies on TD have employed essentially subjective measurement 
techniques, and have been based either upon analysis of cumulated 
clinical reports (used frequently in earlier surveys upon large patient 
samples) or upon individual direct global appraisal of dyskinesia. This 
latter approach was later elaborated into rating scale assessments giving 
discrimination of severity in different body areas. With more complicated 
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-scoring techniques, so designed in order to identi-fy -fine quantitative 
•fluctuations in dyskinetic movement, rater skill in terms of 
reproducibility (test:retest and inter-rater reliability) represents an 
area of technical weakness. It is possible that some reported variation 
in intensity o-f abnormal movements in fact represents subjective 
variation in rater rather than in objective clinical symptoms (Bergen et 
al,1984). Attempts to evolve too -fine a system may thus be sel-f-limiting 
and in -fact achieve inconsistencies rather than degrees of precision 
perhaps not essential for the job in hand. No ideal system of measuring 
abnormal movements that is suited to all test requirements has been 
evolved, and methods convenient for use in prevalence surveys may not be 
sensitive enough to detect alterations in response, either amelioration 
or intensification of dyskinesia, to different drugs. Variety of 
methodological approaches over the years has contributed in no small way 
to the variation of reported TD prevalence figures found in different 
studies. 
2.4.6.1 Global evaluation 
Most of the better designed studies since 1975 have tended to employ 
detailed and standardised examination of each patient. Detailed 
individual clincial evaluation is difficult and time consuming when 
involving large patient groups, and big sample surveys t^ave generally 
utilised simpler global evaluations of dyskinesia. In review of 56 case 
studies Kane and Smith (1982) found the prevalence of TD to average i-3.9/. 
in those studies employing nominal (yes/no) categorisation, while 24.47. 
was averaged in studies using severity scales; there was a clear tendency 
49 
for larger samples to yield lower prevalence rates. To date the lowest 
recorded prevalence rate is 0.57. derived from a massive sampling 
totalling some 10,019 patients (Hoff and Hoffman,1967); this large survey 
was based on heterogenous populations from 14 different institutions with 
many physicians contributing inconsistent data. The overall incidence of 
TD in the study ranges from 07. to 8'/. and is attributable to the fact that 
data was provided by staff members in charge of various wards. The 
weakness of this particular study is the system used to assemble clinical 
data which was similar to, and therefore having all the disadvantages of, 
the questionnaire technique of collecting epidemiological data, 
especially in the absence of objective criteria for the assessment of TD. 
2.4.6.2 Movement frequency 
This technique involves counting the number of oral movements, such as 
tongue protrusions, opening of the mouth or lip pouting, observed per 
minute. The timed count has been converted into a rating score by some 
investigators. Approaches based on movement counts are usually used as 
one of a number of different rating criteria, principally in trials of 
the therapeutic effects of drugs on TD (Quinn and Marsden,1984). Clearly 
measurements of this type reflect only focai dyskinetic activity, but as 
such are amenable to the application of more oQjective 
electrophysiological techniques. Oral dyskinesias have been recorded via 
electrodes placed on the right and left sides of the upper and lower lip, 
or signals from a pneumatic transducer placed in a balloon in the 
patient's mouth. Although sensitive, electrical methods present problems 
as to the validity of their results since the circumstances of the 
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investigation are stressful for the patient and there may be practical 
difficulties in getting patients to cooperate, also the recorded curve 
does not distinguish between physiological and pathological movements of 
various kinds. 
2.4.6.3 Severity rating scales 
Clinical rating protocols are currently accepted as the most practical, 
reasonably valid and consistent means for quantitative assessment of 
abnormal movements, and they are utilised regularly in literature dealing 
with the subject of TD. The intensity of dyskinesia in different regions 
of the body is evaluated by means of a global-item or multi-item rating 
scale, generally scored from 0 rising to 3 or 4 thus representing 4 to 5 
points of severity, depending on individual test format. The variety of 
rating systems evolved differ mainly in the manner of breakdown of the 
hyperkinetic movement categories, the inclusion or otherwise of scores 
for amplitude or duration, and assessment of concomitant parkinsonian 
features such as tremor, facial expression, etc. None of the publisned 
scales are considered completely error—free and standardised videotaping 
with blind rating of cases is often added to sharpen rater reliability. 
Two of the mare widely used of these rating systems are the Kockland 
Scale (Simpson et al,1979) and the' Associated Involuntary Movement Scale 
(Guy,1976) - this latter is perhaps better favoured on account of desiqn 
simplicity (Owens et al,1982), offering a brief yet adequate instrument 
for the assessment of TD (Smith et al,1979). 
The AIMS measures the presence and severity of abnormal movements in 7 
areas of the body, vis. muscles of facial expression; lips - perioral 
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zone; jaw; tongue; upper extremities; lower extremities and trunk 
(neck:shoulders:hips). Ratings of tremor are specifically excluded, and 
follow a 5 point severity scale in all areas (0 = none; 1 = minimal or 
extreme normal; 2 = mild; 3 = moderate; 4 = severe). Additional global 
items judge features such as overall severity of abnormal movements, 
patient's subjective awareness of, and distress by, the abnormal 
movements, and record comment on the past or present wearing of dentures. 
Simpson's Rockland Scale records specified abnormal movements on a 
severity continuum of from 0 (absent) to 5 (severe), and allows 
construction of a detailed profile of abnormality. A total of 34 items 
schedule particular movements to be rated, and 9 are for other 
unspecified abnormal movements; the items are arranged regionally and 
numerically, viz. face, neck and trunk, upper and lower limbs, and whole 
body. 
The more detailed and sensitive a scale, the greater the demands on the 
raters, and berlach (1979) has ennumerated the advantaqes provided by the 
application of video techniques as an aid to improved observations, 
increased sensitivity, reliability and validity. 
With reference to the rise in popularity of severity ratings, Kane and 
Smith (1982) noted that increased 'use of such ratings could be positively 
correlated with increase in reported prevalence rates. One-way analysis 
of variance indicated that prevalences based on rating scales showed 
elevation from the 1960's to the 1970's, while those based on nominal 
categorisation failed to demonstrate any significant change from one 
decade to the next; it was concluded however that this increase in 
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reported prevalence could not be attributed entirely to the increased use 
o-f rating scales. Rating scale studies have contributed 2 of the hignest 
TD prevalence figures published to date, namely 51.67. (Crane and 
Smeets,1974) and 56.4"/. (Jus et al,1976). 
2.4.6.4 Instrumental methods 
Test-retest reliability of rating scales has tended to be disappointing, 
and in the case of TD this has been suggested to be due to temporal 
fluctuations of the syndrome. In order to obviate subjective observer 
error a number of elegant and complex techniques have been evolved which, 
by virtue of their need for technically elaborate equipment, are often 
unsuitable for general routine application to large patient numbers 
(Buruma et al,1983). 
Errors resulting from a high frequency of movements or shifting of the 
movements to different parts of the body can be remedied by the filming 
or videotaping of patients, a technique already alluded to aoove. In the 
case of orofacial dyskinesia film records should be supplemented with 
sound track to distinguish between voluntary speech and dyskinesia. 
Time-lapse photography has been employed in the 'flashlight hold test', 
which is a functional disorder assessment consisting of a flashlight 
attached to each hand of a patient seated in a darkened room. 
Voice recording has further application in a variety of speech assessment 
tests. Since patients with TD display bucco - facie - lmqual 
hyperkinesis and dyscoordination, it is postulated that these 
disturbances are reflected in altered articulative abilities. Imprecise 
articulation, breathy voice quality, nasality and intensity range during 
conversation or on sustained vowel sounds have been analysed by sound 
separation electronic equipment. Such speech studies are usually used as 
adjuncts to rating scale assessments (Fann et al,l?77). 
Electrophysiological contact methods include triaxial accelerometry, orai 
pneumatic transducers and surface polygraph E.M.G. techniques. Although 
the precision of these instruments is far superior to observer judgement, 
the apparatus tends to hamper the patient and so may influence abnormal 
movements to some degree. Non-contacting unobtrusive techniques based 
upon ultrasound (Hains and Sainsbury,1972), and more recently 
doppler-radar (Buruma et al,19S2), appear to have vaiue in the 
investigation of drug effects but are clearly limited in application 
since they require a signal transmitter and receiver, as well as a 




PATIENTS AND METHODS 
3.1 HOSPITAL PATIENT INFORMATION 
This work surveyed the prevalence of abnormal body movements in a 
marginally selected large heterogenous group o-f ambulatory White patients 
•from 14 extended stay wards. All cases were regarded as suffering from 
established serious mental illness in that they were either unable to 
subsist independently of institution staff care, or that their mental 
state fluctuated too widely to permit stable social interaction. 
Hospitalisation for not less than 4 years in Town Hill hospital was taken 
as the minimum to qualify for inclusion in the study but many of the 
patients had been hospitalised for considerably longer periods. 
Most patients were receiving, or had received, antipsychotic medication 
with or without additional anticholinergic drugs, however difficulties 
with patient records made it impossible to obtain accurate prescription 
data in ail cases and any attempt to estaDlish overall neuroleptic intake 
patterns was abandoned as unreliable. 
The psychiatric diagnosis attached to individual patients was taken as 
that recorded on the case file except that grouping of certain disorders 
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under collective headings was done to facilitate analysis as indicated 
below. No fully bedridden or cognitively incapacitated individuals from 
geriatric wards were included to avoid weighting with senile patients. A 
history of previous electroplexy was not considered to be of notable 
relevance since there is little controlled evidence to support an 
association between such therapy and TD (Kane and Smith,1982). 
3.2 DYSKINESIA ASSESSMENT 
In order to obtain unbiased blind ratings, whenever possible the physical 
assessment of abnormal movements was completed without reference to the 
psychiatric diagnosis of patients being scrutinised, although in some 
instances particular cases were already familiar to the examiner. 
Individual clinical ratings were determined by means of a standard three 
stage sequential examination. 
3.2.1 Screening 
Each patient was briefly checked for the presence of dyskinesia accordinq 
to a modification of the Abnormal Involuntary Movement Scale (AIMS) in 
the following manner: 
a) Kinetic examination, in which the subject was observed walking 
unassisted both in and out of the examination roam, as well as walking to 
and fro some 5 paces with arms extended straight in front. Opposition of 
each finger to thumb several times separately with either hand was also 
checked while standing. 
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b) Static examination, with the subject seated in a straight 
backed chair without arms, both -feet firmly on the floor and hands 
resting unsupported on knees or lap. During this time the patient was 
engaged in quiet general conversation. Further examination was made with 
the patient standing erect to attention and with arms outstretched. 
c) Examination of the tongue at rest in the mouth as well as 
extended from the oral cavity; if applicable a check on denture fit was 
done. 
3.2.2 Scoring 
Patients noted to manifest any abnormal involuntary movement were 
re-examined without any attempt to evaluate the nature of the dyskinesia, 
which was then measured on a 4 point duration rating, item grouped to 
define involvement of specific body areas (Kidger et al,l980) in the 
following format:-
Duration: 
0 = movement absent. 
1 = movement present < 50*/. of observed period. 
2 = movement present > 507. of observed period. 
3 = movement continuous. 
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Item Group: 
Component 1 - Lips; Tongue; Jaw; Neck. 
Component 2 - Trunk; Arms; Hands; Legs. 
Component 3 - Lip/Hand tremor ( 0:absent, or 1:present). 
3.2.3. Neurological check 
A brief routine clinical examination was performed to identify 
individuals with isolated focal neurological signs of nonspecific 
diagnostic significance. Such patients were further excluded from the 
survey. 
3.2.4. Diagnostic categories 
Based upon individual ward file diagnosis, ail cases manifesting abnormal 
movements were incorporated into 5 general •'type-'' diagnostic categories 
for further analysis:-
a) Schizophrenic disorder - all forms. 
b) Affective disorder -all forms. 





d) Detective mental development. 




4.1 FINDINGS AND FIGURES 
i/ The entire survey sample (SS group) was composed of 190 males (M) and 
98 females (F) , the mean age of the farmer being 50.8 years (ranging from 
22 to 85) and the latter 57.2 years (ranging from 27 to 84). 
ii/ Of the SS group cases (N = 288), a total of 83 cases (48 rl + 35 F) 
were identified as manifesting apnormal involuntary movements (AM group). 
iii/ The ages of the SS group, both M and F patients, conformed closely 
to a normal distribution pattern, with the F curve showing a mild skewing 
to the right. Age distribution patterns of the AN group, both sexes, were 
almost identical with corresponding elements of the SS group (Figures 1 
and 2). 
iv/ Ward file diagnoses of the AM group are itemised in Table II 
(Appendix) and depicted in Figure 3. Combination of the various diagnoses 
into broad 'type1 categories indicates that the largest number of cases 
with involuntary movements is represented by the 'schizophrenic disorder' 
group (26 M + 16 F), followed by '"organic disorder' (11 h + 10 F) and 
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'defective mental development' (9 M + 5 F); very few cases of 'affective 
disorder' (1 M + 2 F) and 'neurological disorder' (1 H + 2 F) appear in 
this study (Figure 4). 
v/ The 'affective disorder' group consists entirely of manic-depressive 
illness (N = 3) and the 'neurological disorder' group of Huntington's 
chorea (N = 3). 
vi/ Abnormal movement subtype analysis of the AM group shows the 
following component distribution:-
Component 1 (C/l) - 21 cases (13 M + 3 F); 
Component 2 (C/2) - 44 cases (26 M + 18 F); 
Component 3 (C/3) - 2 cases ( 0 H + 2 F); 
Component 1 ?•< 2 (C/l?<2) - 16 cases ( 9 M + 7 F). 
vii/ The subtype C/3 (hand-lip tremor) is considered to correlate with 
parkinsonian clinical features (Kidger et al,1980). In order to isolate a 
patient group whose abnormal movements equate most closely with the 
entity designated 'tardive dyskinesia', the C/3 cases and the 
'neurological disorder' cases (all being C/2 subtypes) were excluded from 
the AM group, leaving a final TD sample at" 78 patients (47 M + 31 F) and 
yielding an overall prevalence figure of 277. (16.31% M + 10.767. F). 
viii/ Schizophrenia forms the major diagnostic category in the TD group, 
being distributed throughout the entire sample in patients below the aqe 
of 80 years (Figure 5). However the cumulative proportion of 
schizophrenic patients with dyskinesia tends to decline with increasing 
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age (Figure 6), and in the period -from the fourth decade onwards organic 
disorders show increasing prominence. None of the schizophrenic patients 
examined were overtly psychotic and the abnormal movements observed were 
not considered to be mannerisms or stereotypies. 
ix/ Patients with orofacial movements (subtype C/l) constitute some 27'/. 
of the TD sample (13 M + 8 F; average age: 64 years) and is the group 
that appears to most closely resemble the original 'bucco - linguo -
masticatory" syndrome. Trunk-limb movements (subtype C/2) occur in 52.5% 
of cases (25 M + 16 F; average age: 43 years) and face-Dody combinations 
(subtype C/1&2) in 20.57. (9 M + 7 F; average age: 62 years). These 
findings suggest that midline dyskinesia of the lower face is a more 
common feature in older patients. The subtype distribution of the TD 
sample is shown in Figure 7. 
x/ The most severe dyskinesias (rating 2 or 3) were encountered in the 
patients with Huntington's chorea. Within the TD sample 77"/. of cases (42 
H + 18 F) achieved rating 1, with 19.27. (3 M + 12 F) and 3.87. (2 M + 1 F) 
achieving rating 2 and 3 respectively; no relationship trends could be 
discerned between the age, sex, diagnosis or dyskinesia subtype of cases 
and the rating scores obtained (Table II - Appendix). None of the rare 
dyskinesia syndromes were encountered, and none of the patients with 
orolingual dyskinesias (subtype C/10 were considered to have dental 
problems, although this was the group with hignest mean age. 
66 
CHAPTER 5 
DISCUSSION OF RESULTS 
5.1 CRITICAL OVERVIEW 
This survey of 228 White patients (190 M + 98 F) has shown that abnormal 
involuntary movements were present in almost 297. of cases examined. The 
prevalence of the various specific forms of dyskinesia in the entire 
sample were as follows:-
Huntingtans' chorea - 1.047. ( 3 cases). 
Parkinsonism - 0.717. ( 2 cases). 
'Tardive' dyskinesia - 27.007. (78 cases). 
Not surprisingly the vast majority of abnormal involuntary movements were 
representative of the clinical entity commonly designated as TD, presumed 
to be a morbidity consequent upon long term neuroleptic therapy. From the 
figures obtained then it appears that 24.77. of the men (47/190) and 31.67. 
of the women (31/98) examined showed features of the TD syndrome 
(male:female ratio approximately 1:1.3). 
Unavoidable lack of methodological uniformity common in studies of this 
type - alluded to in a previous chapter - is a substantial problem, and 
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thus it may be inadvisable to draw too close comparison with prevalence 
•figures appearing in other reports. However bearing this limited validity 
in mind, some comment is warranted in order to discern trends among the 
many variables associated with iatrogenic movement pathology. 
The TD prevalence figure of 277. is somewhat higher than the 17'/. observed 
in White patients at Valkenberg hospital (Holden et al,1984) and below 
that o-f the Black Natal patients from Ekuhlengeni institution at nearby 
Amanzimtoti (Holden, 1985); moreover it con-forms substantially well with 
many other prevalence rate reports from overseas (Kane et al,1980). While 
the methodology is in general similar to that used by Holden et al 
(1984), there are points of difference which could contribute to 
differing results. Although an almost identical patient type and numder 
was surveyed by Holden, the cases with abnormal movements were not 
isolated by individual examination but identified "on the basis of 
personal rounds and interviews with physicians - in - charge and nurses". 
It is possible that certain patients with minor and/or transient abnormal 
movement could have been overlooked in selection for further examination. 
Another significant point of difference is that each of Holden's cases 
were rated independently by 3 raters (although high agreement between 
raters was reported). In the present study examination and rating was 
carried out entirely by one person, a feature which is conducive to 
uniformity of assessment, but although eliminating the problem of 
interrater unreliability, is vulnerable to the objection that no 
independent validation of subjective clinical assessment was operative 
(fluctuating rater error). A further criticism in similar theme, also 
applicable to Hoi den's Valkenberg study, is that cases with abnormal 
movements were subjected to only single clinical examination so that no 
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test-retest validation was possible. Hence patients manifesting transient 
or fluctuating dyskinesias could either be missed (lowering prevalence) 
or included (spuriously boosting prevalence); single examination 
precludes identification of reversible or transient dyskinesias which in 
fact are regarded by some as not representing genuine TD. Although all 
effort was made to achieve 'blind' rating, the diagnoses of several 
patients screened was known to this examiner. It is possible therefore 
that certain minor trunk-limb (subtype C/2) movements, particularly in 
the many schizophrenic patients in the sample, could have been too 
sensitively perceived and interpreted as dyskinesia; this may be a point 
of some relevance particularly in view of the fact that 77"/. of the 
abnormal movements are of the rating 1 group, and 52.5'/. of cases of C/2 
subtype. On the other hand chronic schizophrenic patients, both drug 
treated and untreated, have been found to manifest a remarkably high 
prevalence of involuntary movements (Owens et al,1982); Holden's 
Valkenberg sample reportedly comprised only 47'/. of schizophrenias wnereas 
this study involves 547., a feature which could to some extent contribute 
to a higher prevalence figure. Holden et al (1984) have not attempted to 
relate diagnostic categories to dyskinesia subtype. 
As anticipated the overall TD prevalence rate is a function of the 
criterion level for inclusion. Disregarding minimal score ratings and 
using a criterion level of 2 and above, a reduction of computed 
prevalence to around 77. is obtained and indicates a remarkable paucity of 
obtrusive abnormal movements in the Town Hill patient sample. 
This study shows an insignificant sexual difference in TD prevalence, a 
finding congruent with that of Holden et al (1984) and numerous other 
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publications, indicating that preponderance of women among TD patients is 
an inconstant -feature. The classical buccolingual movements considered to 
typify TD were found to occur in only about one in four of cases, 
although an almost similar number manifested both face and body 
movements. The rest of the patients presented variations of trunk-limb 
dyskinesia and were classified as subtype C/2 in this study. This latter 
category thus comprises movements which many clinicians would recognise 
as congeners of the TD syndrome, although their inclusion is not widely 
accepted. Several of these movements of trunk and limbs could be 
interpreted as restless or fidgety movements such as appear in akathisia, 
however none of the patients included reported subjective feelings of 
restlessness and the symptom may be considered to represent 'late onset 
akathisia' or ' pseudoakathisia' in which the subjective aspects are less 
obtrusive. Since this movement disturbance is both difficult to treat and 
seems frequently associated with TD (Simpson,1977) it has been suggested 
that C/2 represents a peripheral subsyndrome of TD (Kidger et al,1980). 
The average age of patients in this study showing the peripheral TD 
syndrome was 48 years as opposed to an average in excess of 60 years in 
patients with the orofacial syndrome. 
Since no untreated matched patient sample has been examined it is 
difficult to say exactly to what extent spontaneous dyskinesia 
contributes to the number of patients manifesting abnormal movements. 
However at least 12 of the patients were not currently under neuroleptic 
treatment and had, as far as could be ascertained, not been taking such 
medication for at least 4 months prior to the time of examination, if 
these cases were omitted from the TD group, the overall prevalence of TD 




6.1 THE PROBLEM OF TARDIVE DYSKINESIA 
Within the context o-f the -findings reported in Chapter 5, and as a 
critical final summary o-f certain unresolved issues, it is possible to 
•formulate three questions which form a framework for speculative thought 
on the problem. 
6.1.1 Is TD a specific entity? 
The abnormal movements that are described as typifying TD may occur 
spontaneously without prior drug intake, and similar movements -
including the characteristic orofacial syndrome - have been known to 
occur in a variety of physical conditions. Such facts emphasise wnat has 
been pointed out by several writers (Altrocchi, 1972, Turek.,1975, 
Marsden,1985), namely, that spontaneous involuntary movements affecting 
predominantly lower-third, midline facial structures, with lesser limb 
and trunk involvement, is a syndrome of several or many causes. The terms 
'orofacial'', which is descriptive, and 'tardive', which makes an 
implication of cause, are not synonymous with regard to dyskinesias. 
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Senile dyskinesia presents hyperkinetic movements clinically 
indistinguishable -from TD. This disturbance arises spontaneously in 
elderly subjects never exposed to neuroleptics and is localised mainly to 
the oral regions, especially in individuals having dental problems 
(Sutcher et al,1971). It is also clear that the 'peripheral' components 
o-f TD (limb and trunk dyskinesia) are in no way clinically unique 
phenomena and can occur as manifestations of senile dyskinesia as well as 
neurologically discrete movement disorders such as Huntington's chorea. 
Seemingly the TD syndrome can be postulated to represent simply an 
expression of basal ganglia dysfunction, sometimes precipitated by a drug 
induced DA and ACH receptor activity imbalance. Since the features of TD 
mimic abnormal movements which would otherwise be viewed as 'normal' 
sequelae of senile degenerative changes in the basal ganglia 
(Barbeau,1973), at the pathophysiological level neuroleptics might 
conceivably duplicate changes usually accompanying aging processes. 
6.1.2 Is TD a single entity? 
There is accumulating evidence suggesting that TD likely cannot be viewed 
as a discrete disease. Some relevant paints will underscore heterogenous 
features of this abnormal movement syndrome. 
i/ Outcome Aspect : TD should not be regarded as synonymous with 
irreversible dyskinesia, and at least 2 prognostically different clinical 
forms of TD exist viz. persistent and reversible. When TD develops in 
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young patients following long term neuroleptic treatment or following 
withdrawal of such treatment, it often resolves rapidly and hence 
constitutes a relatively harmless phenomenon. Non-resolving TD on the 
other hand is a more frequent characteristic in older patients and can be 
seriously disabling (Jeste and Wyatt,1979). 
ii/ Therapeutic Response Aspect : Chronic neuroleptic 
administration is thought to induce DA receptor denervation 
hypersensitivity with cholinergic - dopaminergic imbalance. However 
results of clinical trials with cholinergic agents have been mixed, some 
patients improved remarkably while others responded little or not at all 
and still others became significantly worse (Moore et al,1980). Such 
finding reveals that only a subgroup of TD patients fits the above 
transmitter imbalance theory and suggests heterogeneity at the 
neurochemical level. 
iii/Phenomenological Aspect : Analysis of the principal movement 
components observed in patients exposed to neuroleptics indicates the 
presence of 3 separate movement dimensions (Kidger et al,1980). One group 
of movements resembles a parkinsonian syndrome, while the other movement 
groups conform to generally accepted criteria for TD, comprising (1) head 
and neck movements, and (2) a range of trunk and limb movements. 
6.1.3 What is the nature of TD? 
Some authors have questioned whether any part of the syndrome described 
as TD can really be attributed to long term neuroleptic administration 
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<Crow et al,1981), and have concluded that spontaneous involuntary 
disorders of movement can be a feature of severe chronic schizophrenia 
unmodified by neuroleptic drugs (Owens,1985). Whatever the merits of such 
arguments may be, it cannot be refuted that the evidence incriminating 
chronic neuroleptic intake as a common cause of abnormal movements is 
epidemiological and inferential. Should it be accepted that usage of 
neuroleptics is causally related to the appearance of TD, it still 
remains to be explained why only some 157.-257. of cases at risk ever 
develop the syndrome. At present there is absolutely no clinical or 
experimental evidence in support of a heredofamilial factor that would 
predispose certain individuals to development of TD. 
If neuroleptics cause potentially irreversible TD then it might be 
expected that these drugs would produce identifiable degeneration of the 
basal ganglia, also that patients with TD would manifest macroscopic or 
microscopic structural pathological changes in the brain. Studies of 
tissue from patients treated with neuroleptics for long periods have 
indeed shown a variety of pathological changes, notably neuronal changes 
and gliosis of the globus pallidus and putamen, inferior olive and 
medulla oblongata, but these changes cannot be regarded as specific. In 
general all investigations, including animal experiments, have failed to 
provide firm evidence of a relationship between neuroleptic treatment or 
TD and neuropathological changes (Gierlach, 1979). 
It would seem there is substantial evidence in support of the contention 
that TD is not at core a loss of structural organisation but is the 
expression of loss of functional resiliency in underlying 
neurotransmitter substrate. This could be viewed as a composite o+ two 
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processes which may contribute variably and concurrently to the 
production of movement disturbance, the first being a transient drug 
induced effect (reversible TD), and the second being a decreased 
plasticity due to aging processes of a 'buffer' which allows 
neurotransmitter mechanisms to absorb neuroleptic drug effects 
culminating in permanent disorder (irreversible TD). In certain 
constitutionally predisposed individuals this latter 'buffer rigidity' 
can manifest spontaneously as senile dyskinesia. 
The finding of an unusual E.E.b. pattern termed 'B-mitten E.E.G. 
dysrhythmia' (Wegner et al,197?) in both TD patients and matched controls 
may be indicative of a pre-existing structural or functional 
vulnerability of the nigrostriatal system to neuroleptic induced 
dysregulation. It is tempting to hazard that this dysrhythmia is an 
electrophysiological reflection of depleted neuronal 'buffer' plasticity. 
In conclusion the crisp comment of Waddington is particularly apt -
"Vulnerability to involuntary movements seems to reside more within the 
brain of the individual patient rather than in how he or she is treated" 
(Waddington,1985). 
6.2 LINES FOR FURTHER RESEARCH 
Clearly the quantity of information emanating from cross sectional 
studies of TD prevalence is substantial, however the numerous problems 
encountered in the control of the many variables involved tend to 
restrict severely the quality and value of data derived therefrom. The 
present cross sectional study, and others of similar design, indicate 
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unambiguously that only carefully planned long term prospective surveys 
on selected large population samples are likely to yield findings that 
will provide clear definition of the risk factors that predispose to, and 
perpetuate the clinical movement disorders associated with neuroleptic 
drug therapy. Of prime importance would be a protocol so designed that in 
the first instance spontaneous senile and 'organic-' choreiform movements 
can be differentiated from the iatrogenic variety, and secondly that 
reversible be distinguished unequivocally from irreversible dyskinesias. 
At the same time more laboratory orientated research should be directed 
towards elucidating precisely the neurophysiological brain mechanisms 
fundamentally involved in the genesis of dyskinetic movements. Although 
coarse morbid anatomical and histological examination of the basal 
ganglia has revealed only nonspecific degenerative pathology, more 
sophisticated techniques such as enzyme histochemistry and 
radioimmunofluoresence would resolve intraneuronal enzyme deficiencies or 
abnormality of cell surface receptor sites. These latter techniques, as 
well as the ligand binding strategies mentioned in an earlier chapter, 
cannot yield reliable information unless applied to fresh brain tissue, a 
stricture that limits applicability of such m vitro approaches 
essentially to work on animal material. 
More practical from the point of view of in vivo human application 
are non-invasive techniques which could detect levels of metabolic 
activity in selected areas of the central nervous system, such as 
positron emission scanning and nuclear magnetic resonance. It also seems 
feasable that well controlled E.E.G. studies enhanced by the use of brain 
electrical activity mapping (Duffy et al,1979, Morihisa et al,1983) could 
76 
be helpful in the identification of brain changes that predispose to 
movement disorders. 
Lastly it appears obvious that understanding of drug induced dyskinesias 
awaits an in depth resolution of the neurophysiological processes 
involved in terms of neurotransmitter interaction and disequilibrium. 
Ne::t to the brain tissue itself, the cerebrospinal fluid is the medium 
which may best reflect neurochemical dysfunctions in the brain. Analysis 
of neurotransmitter metabolites in the cerebrospinal fluid is probably 
the most valuable relatively straightforward technique likely to throw 
light on the pharmacological profile of neuroleptics, both under short 
and long term treatment, thereby evaluating indirectly the mechanisms 
behind the neurological side effects. 
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T A B L E II : PATIENT DATA - AM SROUP (continued) 
DIAGNOSIS SEX AGEiyrsi C/l C/2 C/ 
KORSAKOFF M 59 
KORSAKOFF M 59 
KORSAKOFF M 66 
KORSAKOFF M 67 
KORSAKOFF M 69 
KORSAKOFF M 74 
KORSAKOFF F 57 
KORSAKOFF F 70 
DMD M 35 
DMD M 36 
DMD M 47 
DMD M 55 
DMD M 55 
DMD M 59 
DMD M 68 
DMD M 69 
DMD M 70 
DMD F 37 
DMD F 58 
DMD F 62 
DMD F 75 
DMD F 77 
MANIC-DEPRESSIVE M 35 
MANIC-DEPRESSIVE F 61 
MANIC-DEPRESSIVE F 66 
EPILEPSY M 53 
EPILEPSY F 65 
EPILEPSY F 68 
HUNTINGTON M 37 
HUNTINGTON F 40 


























































































































































































: = 83 
(NOTE : DMD = DEFECTIVE MENTAL DEVELOPMENT) 
